Fate Therapeutics Inc (NAS:FATE)
$ 3.76 0.1 (2.73%) Market Cap: 428.01 Mil Enterprise Value: 135.15 Mil PE Ratio: 0 PB Ratio: 1.01 GF Score: 58/100

Fate Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 01, 2021 / 05:00PM GMT
Release Date Price: $72.46 (-5.40%)
Michael Jonathan Yee
Jefferies LLC, Research Division - Equity Analyst

All right. Well, good afternoon, everyone, and thank you for joining us on our next session. Today, we've got both the CEO, Scott Wolchko; and CFO, Edward Dulac from Fate Therapeutics, a company has certainly been super busy this year with data recently presented and more this month.

So without further ado, I would love to just start off with Scott. And maybe, Scott, you could start maybe with some opening comments about how the Fate platform is progressing with perhaps a focus on data that's been presented recently and data coming up because this is really a big year. I call it last year sort of a breakout year, and this year is sort of a full court press type of year of a lot of data. So maybe just walk us through the progress of Fate and particularly the focus on recent data and what's coming up. That would be a great place to start.

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director

Sure. And I'll do this briefly. So Fate helped pioneer iPS

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot